Viking (VKTX) Q1 2026 earnings review
Clinical Execution is Flawless, But the Bill is Coming Due
Viking Therapeutics is proving it can execute at scale. The company successfully fully enrolled both its massive VANQUISH Phase 3 obesity trials ahead of schedule and laid out a clear roadmap for its oral formulation and novel amylin pipeline. However, transitioning from a mid-stage biotech to a late-stage juggernaut is expensive. R&D expenses accelerated sharply, jumping 263% year-over-year to $150.2M. The company burned approximately $103M in cash this quarter, dropping its reserves to $603M. While clinical progress is undeniable, the financial reality of running concurrent global mega-trials means funding risk is creeping back into the narrative.
🐂 Bull Case
VANQUISH-1 (>4,500 patients) and VANQUISH-2 (~1,000 patients) are now fully enrolled. This rapid uptake derisks the timeline and proves immense investigator and patient appetite for Viking's dual-agonist VK2735.
Viking remains the only major player advancing the exact same molecule in both subcutaneous and oral forms. Moving the oral formulation to Phase 3 in 4Q26 unlocks massive market optionality.
🐻 Bear Case
At a sequential burn rate of ~$103M per quarter, Viking's $603M cash balance offers less than six quarters of runway. A capital raise is highly likely before Phase 3 data reads out.
Incumbents like Novo Nordisk and Eli Lilly are leveraging massive cardiovascular outcomes data to secure reimbursement. Viking currently lacks a dedicated cardiovascular outcomes trial, risking future payer pushback.
⚖️ Verdict: ⚪
Bullish on science, cautious on capital. Management is hitting every clinical milestone perfectly, but the sheer cost of these trials is eroding the balance sheet faster than in previous years.
Key Themes
Clinical Execution at Scale
Viking successfully completed enrollment for the VANQUISH-2 study (~1,000 patients) in Q1, following the early completion of VANQUISH-1. Moving 5,500+ patients into active Phase 3 dosing is a massive logistical hurdle cleared. This speed highlights significant market demand and sets the stage for pivotal readouts.
The Oral Differentiator (Technology Innovation)
The oral tablet formulation of VK2735 is advancing to Phase 3 in 4Q26. If successful, it would be the industry's first oral dual agonist. Using the exact same active ingredient as the injectable version gives Viking a unique advantage in step-down therapy and weight loss maintenance, minimizing the safety risks of switching drugs.
Pipeline Expansion: Amylin Agonist Enters the Clinic
Viking filed an Investigational New Drug (IND) application for VK3019, its novel amylin/calcitonin receptor agonist. Slated for Phase 1 in 2Q26, this gives Viking a second distinct mechanism of action for obesity, critical for patients who cannot tolerate standard GLP-1 therapies.
Accelerating Cash Burn Contradicts 'Strong Cash' Narrative
Management touted a 'strong quarter-end cash position of $603 million.' However, the data shows cash dropped by $103M in just 90 days (from $706M at the end of 2025). With multiple Phase 3 trials now actively dosing, costs will remain elevated, severely limiting the runway compared to the $900M+ safety net Viking enjoyed a year ago.
The Outcomes Data Gap (Macro Competition)
The macro environment for obesity drugs is shifting from 'weight loss' to 'overall health outcomes.' Competitors have established cardiovascular benefit data to secure broad payer coverage. Viking's failure to mention plans for a dedicated cardiovascular outcomes trial leaves a critical vulnerability in its ultimate go-to-market strategy.
Execution Risk on Multiple Simultaneous Fronts
Viking is now attempting to manage a 5,500-patient subcutaneous Phase 3 program, spin up a brand new Phase 3 oral program, finalize a complex Phase 1 maintenance dosing study, and initiate a Phase 1 amylin trial—all simultaneously. For a company of Viking's size, this level of operational load introduces severe execution and supply chain risks.
Other KPIs
Accelerating heavily year-over-year (up from $41.4M in 25Q1), but stable sequentially compared to 25Q4 ($153.5M). This reflects the structural step-up in costs required to actively dose over 5,500 patients in the VANQUISH Phase 3 program, along with scaled manufacturing costs with CordenPharma.
Decelerating. Dropped from $706M at the end of 2025 and over $900M a year ago. While debt-free, the current burn trajectory implies the need for a dilutive capital raise or strategic partnership within the next 12 to 18 months to safely cross the finish line for Phase 3 readouts.
Guidance
Stable timeline. The IND has been successfully filed, officially moving Viking into the highly anticipated amylin space to diversify beyond GLP-1s.
Crucial catalyst. This Phase 1 data will reveal if patients can sustain weight loss by shifting to monthly subcutaneous injections or oral pills—a massive potential advantage for patient retention and payer economics.
Following end-of-Phase 2 meetings with the FDA, Viking is bypassing Phase 2b and jumping straight to a pivotal registration trial. This rapid advancement highlights the FDA's comfort with the shared molecule profile.
Key Questions
Capital Needs and Runway
With cash burn exceeding $100M this quarter and Phase 3 oral trials starting in Q4, do you intend to secure a strategic partner to fund commercialization, or will you raise capital via equity before the end of the year?
Cardiovascular Outcomes Trial (CVOT) Strategy
Given the shifting payer landscape and the massive CVOT data generated by Lilly and Novo, what is Viking's strategy to ensure broad reimbursement without a dedicated outcomes trial currently running?
Oral Phase 3 Trial Design
As you prepare for the oral Phase 3 initiation in 4Q26, will the trial design mirror the VANQUISH program by requiring separate cohorts for standard obesity and obesity with Type 2 Diabetes?